• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.

作者信息

Gallina Filippo Tommaso, Balzano Vittoria, Porciello Nicla, Tajè Riccardo, Forcella Daniele, Melis Enrico, Letizia Cecere Fabiana, Fusco Francesca, Buglioni Simonetta, Visca Paolo, Nisticò Paola, Cappuzzo Federico, Spicer Jonathan

机构信息

Thoracic Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.

Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

出版信息

Lung Cancer. 2024 Aug;194:107900. doi: 10.1016/j.lungcan.2024.107900. Epub 2024 Jul 26.

DOI:10.1016/j.lungcan.2024.107900
PMID:39079181
Abstract
摘要

相似文献

1
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.一名接受新辅助化疗免疫治疗的可切除非小细胞肺癌患者的程序性死亡受体配体1（PD-L1）表达轨迹
Lung Cancer. 2024 Aug;194:107900. doi: 10.1016/j.lungcan.2024.107900. Epub 2024 Jul 26.
2
Is neoadjuvant immunotherapy necessary in patients with programmed death ligand 1 expression-negative resectable non-small cell lung cancer? A systematic review and meta-analysis.程序性死亡配体 1 表达阴性可切除非小细胞肺癌患者需要新辅助免疫治疗吗？系统评价和荟萃分析。
Lung Cancer. 2024 May;191:107799. doi: 10.1016/j.lungcan.2024.107799. Epub 2024 Apr 23.
3
Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.新辅助 PD-(L)1 阻断联合铂类化疗治疗潜在可切除的驱动基因阳性非小细胞肺癌。
World J Surg Oncol. 2024 Jun 18;22(1):159. doi: 10.1186/s12957-024-03434-1.
4
The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis.PD-L1 在接受新辅助免疫检查点抑制剂联合化疗的非小细胞肺癌患者中的作用：一项荟萃分析。
Sci Rep. 2024 Oct 31;14(1):26200. doi: 10.1038/s41598-024-78159-y.
5
PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.PD-L1 ≥ 50% 的肺癌对 PD-1 抑制耐药：挽救性化疗免疫联合治疗的作用。
Immunotherapy. 2021 Apr;13(5):363-369. doi: 10.2217/imt-2020-0280. Epub 2021 Feb 3.
6
Facts and Hopes in Neoadjuvant Immunotherapy Combinations in Resectable Non-Small Cell Lung Cancer.可切除非小细胞肺癌新辅助免疫治疗联合方案中的事实与希望
Clin Cancer Res. 2025 Mar 3;31(5):801-807. doi: 10.1158/1078-0432.CCR-24-1441.
7
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
8
The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis.新辅助免疫化疗在可切除的I-III期非小细胞肺癌中的疗效和安全性：一项系统评价和网状Meta分析
Clin Transl Oncol. 2025 Apr;27(4):1493-1505. doi: 10.1007/s12094-024-03704-0. Epub 2024 Sep 9.
9
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.低PD-L1表达的非鳞状非小细胞肺癌化疗免疫治疗方案的选择：一项多中心回顾性队列研究
Clin Lung Cancer. 2025 May;26(3):e190-e198.e4. doi: 10.1016/j.cllc.2025.01.002. Epub 2025 Jan 4.
10
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与含或不含贝伐珠单抗的一线含铂化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2.